ViroPharma Announces Positive CHMP Opinion for Buccolam in the European Union

ViroPharma Incorporated VPHM earlier today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization for Buccolam, for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years. If approved by the European Commission, Buccolam would be the first product approved through the centralized PUMA procedure.